Comment
doi: 10.1016/S2213-8587(14)70002-6.
Epub 2014 Jan 24.
Dreaming of normoglycaemia with fewer diet restrictions
Affiliations
- PMID: 24795239
- DOI: 10.1016/S2213-8587(14)70002-6
Item in Clipboard
Comment
Dreaming of normoglycaemia with fewer diet restrictions
Lancet Diabetes Endocrinol.
2014 May.
No abstract available
Comment on
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Lancet Diabetes Endocrinol. 2014. PMID: 24795251 Clinical Trial.
Similar articles
-
Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD?Nat Rev Nephrol. 2014 Apr;10(4):181. doi: 10.1038/nrneph.2014.20. Epub 2014 Feb 18. Nat Rev Nephrol. 2014. PMID: 24535419 No abstract available.
-
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus.Am Fam Physician. 2016 Dec 15;94(12):1014-1015. Am Fam Physician. 2016. PMID: 28075091 Review. No abstract available.
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2016 Mar 17;374(11):1093-4. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981944 No abstract available.
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med. 2016 Mar 17;374(11):1093. doi: 10.1056/NEJMc1600827. N Engl J Med. 2016. PMID: 26981943 No abstract available.
-
In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.Am Fam Physician. 2016 Mar 1;93(5):410. Am Fam Physician. 2016. PMID: 26926979 Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
